Phlebaven, 500 mg 32 pcs

The drug Phlebaven^® is indicated for the therapy of symptoms of chronic vein diseases (elimination and relief of symptoms).

Therapy of symptoms of venous and lymphatic insufficiency:

• pain;
• lower limb cramps;
• sensation of heaviness and expansion in legs;
• “tired legs”

therapy of manifestations of venous-lymphatic insufficiency:

• lower extremity edema;
• trophic changes of the skin and subcutaneous tissue;
• venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Composition

for 1 tablet

Kernel:

Purified micronized flavonoid fraction, substance-granules 613.00 mg

[Active substance substance-granules:

Purified micronized flavonoid fraction [diosmin (90%) 450 mg, flavonoids converted to hesperidin (10%) 50 mg] 500.00 mg

Auxiliary substances of substance-granules:

Microcrystalline cellulose, povidone K-30]

Auxiliary substances:

Sodium carboxymethyl starch, talc, magnesium stearate

Shell film:

Opadray Orange 03H325991

1 Opadray Orange 03H32599 contains:

– hypromellose

– -titanium dioxide (E171)

– talk

– propylene glycol

– – yellow iron oxide dye (E172)

– – Red iron oxide dye (E172)

How to take, the dosage

Orally.

The recommended dose for venous-lymphatic insufficiency is 2 tablets per day (in one or two doses): in the morning, during the day and/or in the evening, with meals.

The duration of treatment may be several months (up to 12 months). In case of recurrence of symptoms, upon the doctor’s recommendation, the course of treatment may be repeated.

The recommended dose for acute hemorrhoids is 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days.

The recommended dose for chronic hemorrhoids is 2 tablets per day.

Interaction

Not noted.

Make sure you tell your doctor about all the medications you are taking.

Special Instructions

Please see your doctor immediately if your condition worsens or does not improve with treatment.

No effect.

Synopsis

Capsule-shaped, biconvex, film-coated tablets with light orange-pink color.

Breakage appearance of the tablets: rough yellow to brownish-yellow mass with light orange-pink film coating.

Contraindications

Side effects

Side effects of the combination hesperidin + diosmin observed in clinical trials were mild. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were mostly observed.

World Health Organization (WHO) recommended side effect frequency classification:

very frequently ≥1/10

often ≥ 1/100 to < 1/10

infrequently from ≥ 1/1000 to < 1/100

rarely from ≥ 1/10000 to < 1/1000

very rarely < 1/10000

frequency is unknown cannot be estimated from available data.

From the central nervous system:

rarely: dizziness, headache, general malaise.

From the digestive system:

often:diarrhea, dyspepsia, nausea, vomiting;

Overdose

No cases of overdose have been described.

In case of overdose of Flebaven®, seek medical attention immediately.

Pregnancy use

Pregnancy

Animal experiments have not shown teratogenic effects.

Till now there were no reports of adverse effects when using the drug in pregnant women.

Breast-feeding

Due to the lack of data regarding excretion of the drug with the breast milk, women during breast-feeding should not take the drug.

Effects on reproduction

Reproductive toxicity studies have shown no effects on reproduction in rats of either sex.

Similarities